A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Latest Information Update: 06 Jun 2024
At a glance
- Drugs HR 19042 (Primary)
- Indications IgA nephropathy
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Oct 2021 Status changed from not yet recruiting to recruiting.
- 26 Aug 2021 New trial record